Global Blood Therapeutics Inc (NASDAQ:GBT) – Oppenheimer issued their FY2022 earnings estimates for Global Blood Therapeutics in a note issued to investors on Thursday, Zacks Investment Research reports. Oppenheimer analyst M. Breidenbach anticipates that the company will post earnings of $4.30 per share for the year. Oppenheimer has a “Buy” rating and a $79.00 price target on the stock.
Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the business posted ($0.58) EPS.
Several other equities analysts have also recently commented on the stock. ValuEngine upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. William Blair assumed coverage on shares of Global Blood Therapeutics in a research report on Tuesday, January 23rd. They issued an “outperform” rating and a $80.00 target price for the company. HC Wainwright set a $73.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 11th. BidaskClub cut shares of Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 20th. Finally, Wedbush restated an “outperform” rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a research report on Friday, December 15th. Two equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $63.27.
Global Blood Therapeutics (NASDAQ:GBT) opened at $60.80 on Friday. The company has a market cap of $2,800.00 and a P/E ratio of -23.84. Global Blood Therapeutics has a 12-month low of $15.75 and a 12-month high of $64.50.
In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $36.55, for a total transaction of $109,650.00. Following the sale, the insider now directly owns 135,255 shares of the company’s stock, valued at approximately $4,943,570.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Perceptive Advisors Llc bought 175,000 shares of Global Blood Therapeutics stock in a transaction on Tuesday, December 19th. The shares were acquired at an average cost of $38.00 per share, for a total transaction of $6,650,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 51,812 shares of company stock worth $2,864,728 over the last ninety days. 5.30% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Emory University bought a new stake in Global Blood Therapeutics during the 2nd quarter worth approximately $1,442,000. Citigroup Inc. grew its holdings in Global Blood Therapeutics by 1,544.9% during the 2nd quarter. Citigroup Inc. now owns 87,819 shares of the company’s stock worth $2,402,000 after acquiring an additional 82,480 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Global Blood Therapeutics by 211.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 317,571 shares of the company’s stock worth $8,686,000 after acquiring an additional 215,690 shares during the last quarter. Family Management Corp bought a new stake in Global Blood Therapeutics during the 3rd quarter worth approximately $351,000. Finally, Perceptive Advisors LLC grew its holdings in Global Blood Therapeutics by 8.4% during the 3rd quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock worth $132,399,000 after acquiring an additional 330,139 shares during the last quarter. 85.83% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/05/global-blood-therapeutics-inc-expected-to-earn-fy2022-earnings-of-4-30-per-share-gbt.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.